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Abstract
Background: We have previously demonstrated that high tumor tissue levels of TIMP-1 are associated with no or
limited clinical benefit from chemotherapy with CMF and anthracyclines in metastatic breast cancer patients. Here, we
extend our investigations to the adjuvant setting studying outcome after adjuvant chemotherapy in premenopausal lymph
node-positive patients. We hypothesize that TIMP-1 high tumors are less sensitive to chemotherapy and accordingly that
high tumor tissue levels are associated with shorter survival.
Methods: From our original retrospectively collected tumor samples we selected a group of 525 pre-menopausal lymph
node-positive patients (adjuvant treatment: CMF, 324 patients; anthracycline-based, 99 patients; no adjuvant
chemotherapy, 102 patients). TIMP-1 levels were measured using ELISA in cytosolic extracts of frozen primary tumors.
TIMP-1 was analyzed as a continuous variable and as a dichotomized one using the median TIMP-1 concentration as a
cut point between high and low TIMP-1 groups. We analyzed the benefit of adjuvant CMF and anthracyclines in univariate
and multivariable survival models; endpoints were disease-free (DFS) and overall survival (OS).
Results: In this selected cohort of high-risk patients, and in the subgroup of patients receiving no adjuvant therapy, TIMP-
1 was not associated with prognosis. In the subgroup of patients treated with anthracyclines, when analyzed as a
continuous variable we observed a tendency for increasing TIMP-1 levels to be associated with shorter DFS (multivariable
analysis, HR 1.75, 95% CI 1.00-3.07, P = 0.05) and a significant association between increasing TIMP-1 and shorter OS in
both univariate (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and multivariable analyses (HR 4.19, 95% CI 1.67-10.51, P = 0.002).
No statistically significant association between TIMP-1 and DFS was observed in the CMF-treated patients although high
TIMP-1 was associated with shorter OS when analyzed as a dichotomized variable (HR 1.64, 95% CI 1.02-2.65, P = 0.04).
Conclusion: In the subgroup of patients receiving adjuvant chemotherapy we found an association between shorter
survival after treatment in TIMP-1 high patients compared with TIMP-1 low patients, especially in patients receiving
anthracycline-based therapy. This suggests that high tumor tissue levels of TIMP-1 might be associated with reduced
benefit from classical adjuvant chemotherapy. Our findings should be validated in larger prospective studies.
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Many patients are offered adjuvant chemotherapy after
surgery for primary breast cancer. Several options exist
(reviewed in [1]) but currently, adjuvant chemotherapy
only reduces breast cancer mortality by up to 50% [2] and
hence further improvement is needed. Moreover, chemo-
therapy is most often associated with substantial side
effects. In theory, by attacking the tumor cells effectively at
an early stage unnecessary growth and potential selection
of resistant clones is avoided and a better response to
adjuvant treatment is to be expected. Choosing the most
effective adjuvant chemotherapy regimen up front should
thus lead to a further reduction in disease recurrences and,
accordingly, to increased survival of the patients. In addi-
tion, avoiding ineffective treatments would reduce
unneeded toxicity and burden for the patients and the
substantial costs associated with administration of adju-
vant chemotherapy.
Prescription of chemotherapy with no benefit to the
patient could be limited through identification and use of
predictive markers. Predictive markers serve as a tool for
tailoring therapy for individual patients, however, the
number of approved markers in primary breast cancer is
limited [3]. Thus, additional markers are needed to
improve planning of a more personalized adjuvant treat-
ment.
TIMP-1 is a naturally occurring inhibitor belonging to the
matrix metalloproteinase (MMP) system, and besides its
MMP-inhibitory functions TIMP-1 also appears to inde-
pendently influence cell growth and apoptosis (for
reviews, see [4,5]). In metastatic breast cancer patients, we
reported that a high level of TIMP-1 in the primary tumor
tissue is associated with decreased objective response to
chemotherapy [6], and a report showing a similar associ-
ation in the adjuvant setting was recently presented [7]. In
addition, it appears that TIMP-1 may be combined with
TOP2A for prediction of response to anthracycline-based
chemotherapy [8]. Similarly, high levels of plasma and
serum TIMP-1 are associated with a decreased response to
endocrine therapy in metastatic breast cancer patients
[9,10]. Besides the predictive information, which can
apparently be gained from TIMP-1, several publications
demonstrate that high levels of TIMP-1 protein in breast
cancer tissue [11-14], plasma and serum [12,15-17] are
associated with a poor prognosis. Based on these previous
studies, it may be concluded that TIMP-1 appears to carry
predictive as well as prognostic information; it has not
been clarified, though, whether TIMP-1 carries mainly
prognostic or predictive information and whether this
information may be restricted to certain patient sub-
groups.
To further study the possible use of TIMP-1 as a biomarker
in breast cancer patients, the present study investigates the
association between levels of TIMP-1 in cytosolic tumor
tissue extracts and outcome following adjuvant chemo-
therapy with cyclophosphamide-methotrexate-5-fluorou-
racil (CMF) or an anthracycline-containing regimen
(cyclophosphamide and 5-fluorouracil with adriamycin/
epirubicin (CAF/CEF); or single-agent adriamycin (A)), or
following no adjuvant treatment. We hypothesized that
high levels of TIMP-1 are associated with decreased bene-
fit from adjuvant chemotherapy and we investigated this
hypothesis in a cohort of 525 premenopausal lymph
node-positive breast cancer patients, who constitute a
subgroup of a large cohort previously described in several
studies [14,18,19]. First, we evaluated the association with
prognosis in all patients included. The included subgroup
of patients receiving no adjuvant therapy allowed for eval-
uation of association between TIMP-1 and outcome with-
out any influence from adjuvant therapy; by definition,
this is evaluation of prognosis. Secondly, in patients
treated with adjuvant chemotherapy we analyzed the pre-
dictive impact of TIMP-1. The endpoints evaluated in the
present study are DFS and OS. In particular, for the analy-
ses of predictive impact of TIMP-1, DFS is considered the
most informative as this endpoint is not influenced by
subsequent systemic therapy. The Reporting Recommen-
dations for Tumor Marker Prognostic Studies (REMARK
[20]) were adhered to where ever applicable.
Methods
Patients and study design
Tumor tissue extracts included in the present study were
collected between 1979 and 1994. Our protocol for stud-
ying molecular markers associated with disease progres-
sion was approved by the institutional Medical Ethics
Committee of the Erasmus MC Rotterdam (MEC no.
02.953). The present study, in which coded tissues were
used, was performed in accordance with the Code of Con-
duct of the Federation of Medical Scientific Societies in the
Netherlands [21].
Patients were selected for the present study from a cohort
of 2984 breast cancer patients [14] for which the original
inclusion/exclusion criteria are described in [18]. Here,
only patients who had lymph node-positive breast cancer
and who were premenopausal at the time of diagnosis
were included. This is due to the fact that very few post-
menopausal and no lymph node-negative patients
received adjuvant chemotherapy at the time when these
samples were collected. Furthermore, only patients who
received adjuvant chemotherapy with CMF, CEF, CAF or
single-agent A, or who received no adjuvant chemo- or
endocrine therapy were included. Treatment decisions
were based on standard rules at the time. Finally, patients
were included in the present study based on the availabil-Page 2 of 13
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BMC Cancer 2009, 9:322 http://www.biomedcentral.com/1471-2407/9/322ity of information about TIMP-1 concentration in the pri-
mary tissue, originally measured in stored cytosolic
extracts after estrogen and progesterone receptor (ER/PgR)
determination and used for a previous study [14].
A total of 525 patients fulfilled the inclusion criteria; 164
of these were ≤ 40 years, and 361 were 41-55 years.
Among included patients, 292 patients had 1-3 positive
lymph nodes and 233 had more than 3 tumor-positive
axillary lymph nodes. In 175 patients, tumors were ≤ 2 cm
(pT1), 270 patients had tumors larger than 2 cm and ≤ 5
cm (pT2), and 80 patients had tumors larger than 5 cm or
skin or chest wall involvement (pT3+4). Differentiation
grade was well or moderate in 103 tumors, poor in 291
tumors and unknown in 131 tumors. ER/PgR positive
tumors were present in 432 patients. All patients had sur-
gical removal of their tumor (313 mastectomies, 212
lumpectomies) and 391 patients received adjuvant radio-
therapy (RT; of the chest wall and/or local or regional
lymph nodes). A total of 423 patients received adjuvant
chemotherapy; 324 had CMF, 99 had an anthracycline-
containing regimen, and 102 patients had no adjuvant
systemic therapy. The characteristics of the total patient
group as well as subgroups according to adjuvant treat-
ment are summarized in Table 1. In the table, and in the
following parts, the term "Untreated patients" refers to
patients who received no adjuvant therapy; however, it
should be emphasized that these patients were treated
with surgery and some also with adjuvant radiotherapy.
Follow-up consisted of routine examinations every 3-6
months during the first 5 years and once a year thereafter.
Table 1: Patient and tumor characteristics and comparisons of patient groups
Characteristic All patients
N (%)
CMF-treated patients
N (%)
Anthracycline-treated 
patients
N (%)
Untreated patients
N (%)
P1
Age
≤ 40 years 164 (31) 110 (34) 28 (28) 26 (25) 0.212
41-55 years 361 (69) 214 (66) 71 (72) 76 (75)
Involved lymph nodes
1-3 292 (56) 217 (67) 47 (47) 28 (27) <0.0012
>3 233 (44) 107 (33) 52 (53) 74 (73)
Steroid hormone rec. status
Positive 432 (82) 269 (83) 76 (77) 87 (85) 0.242
Negative 93 (18) 55 (17) 23 (23) 15 (15)
Tumor size
pT1 175 (33) 131 (40) 21 (21) 23 (23) <0.0012
pT2 270 (51) 147 (45) 58 (59) 65 (64)
pT3+4 80 (15) 46 (14) 20 (20) 14 (14)
Grade
Well/moderate 103 (20) 65 (20) 21 (21) 17 (17) 0.332
Poor 291 (55) 174 (54) 61 (62) 56 (55)
Unknown 131 (25) 85 (26) 17 (17) 29 (28)
Primary treatment
Lumpectomy 212 (40) 169 (52) 4 (4) 39 (38) <0.0012
Mastectomy 313 (60) 155 (48) 95 (96) 63 (62)
Events3
Recurrences (disease failure) 268 140 58 70
Deaths 149 75 32 42
TIMP-1 (median, range) 12.5 (0- 113) 12.0 (0- 106) 13.5 (0-51.2) 13.8 (0- 113) 0.204
All patients, N = 525; CMF-treated patients, N = 324; anthracycline-treated, N = 99; untreated patients, N = 102.
1Testing the hypothesis that subgroups (CMF- or anthracycline treated and untreated) are similar
2Pearson X2 test
3Events when censored at 60 months
4Kruskal-Wallis equality-of-populations rank testPage 3 of 13
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9-255) months (CMF-treated patients, 103 (range, 12-
248) months; anthracycline-treated patients, 90 (range, 9-
213) months; untreated patients, 93 (range, 15-255)
months).
Median survival of patients alive represents median obser-
vation time.
Assays and tumor specimens
TIMP-1 concentrations were originally determined for use
in a large study of the association between TIMP-1 and
prognosis, and this study also included validation of the
assay with the present extraction buffer [14].
In brief, tumor tissue specimens were prepared following
instructions from the European Organisation for Research
and Treatment of Cancer (EORTC) regarding extraction of
tumor tissue for determination of cytosolic ER and PgR
[22]. Levels of TIMP-1 in the cytosols were measured
using an established, validated in-house enzyme-linked
immunosorbent assay (ELISA) [23]. Concentrations of
total protein were measured using the Coomassie Brilliant
Blue Method (Bio-Rad Laboratories, Hercules, CA). ER
and PgR levels were assessed previously by ligand-binding
assay or enzyme immunoassay as described in [24] and
the cut point used for classification as ER/PgR positive or
negative was 10 fmol/mg of protein.
Data analysis and statistics
Differences in TIMP-1 levels were assessed with the Mann-
Whitney U test or the Kruskal-Wallis equality-of-popula-
tions rank test when appropriate. In these tests, patient
and tumor characteristics were used as grouping variables.
Associations between continuous variables were tested
with the Spearman rank correlation (rs). Differences
between treatment groups were tested with the Pearson X2
test. Cox proportional hazard models were applied to
compute the hazard ratio (HR). Disease-free survival
(DFS) and overall survival (OS) were used as endpoints.
For DFS any relapse or secondary breast cancer was
counted as failure; non-failing patients were censored at
last date of contact. For OS, death of any cause was
counted as a failure. Surviving patients were censored at
last day of follow-up.
The protocols for adjuvant treatment (RT on the axilla
and/or systemic therapy), depending on the number of
tumor-positive lymph nodes (1-3, >3), were changed dur-
ing the study period. To accommodate these changes we
used a combination of nodal status (1-3, >3) and RT on
the axilla (no, yes) to stratify all analyses.
Proportional hazards assumptions were tested based on
Schoenfeld residuals. As to be expected, the proportional
hazards assumption was violated for hormone receptor
status and accordingly, all analyses were stratified for hor-
mone receptor status (negative, positive). Hence, none of
the variables used for stratification (nodal status, RT, hor-
mone receptor status) were included in the multivariable
analyses. Age, tumor size, and malignancy grade defined
the base model to correct for classical prognostic factors.
In multivariable analyses TIMP-1 was added to this
model. In none of these analyses the proportional hazards
assumption was violated.
To reduce skewness of the distribution of TIMP-1 levels,
these were log-transformed. No interactions were
observed between TIMP-1 and the classical prognostic fac-
tors or adjuvant therapy in the analysis for DFS. The inter-
action analysis investigates whether the contribution to
the survival model of the one variable is dependent upon
the values of the other; the estimates for the survival
model will be different for the subgroups if there is an
interaction [25].
TIMP-1 levels were dichotomized by the overall median
(12.5 ng/mg of total protein). Dichotomized levels were
used for the survival curves using the method of Kaplan
and Meier.
In this dataset, three groups relating to systemic adjuvant
treatment were available: patients treated with CMF,
patients treated with anthracyclines, and patients who
received no adjuvant chemotherapy. In the analyses of all
patients we used the group receiving no adjuvant chemo-
therapy as the reference group. For both endpoints (DFS,
OS), the hypothesis that these untreated patients are not
different, regardless of tumor tissue TIMP-1 levels (low,
high), was maintained.
For all analyses, the survival times were censored at 60
months because the numbers of patients at risk in some
treatment groups were low at 5 years; the numbers of
patients at risk in the treatment subgroups appear from
the figures (Figure 1, 2 and 3).
Computations were performed with the STATA statistical
package, version 10.1 (STATA Corp., College Station, TX).
All P-values are two-sided and P < 0.05 was considered
statistically significant.
Results
Characterization and comparison of patient subgroups
Patients were subdivided according to adjuvant chemo-
therapy regimen received (CMF, 324 patients; anthracy-
cline-containing, 99 patients; no adjuvant chemotherapy,
102 patients). Table 1 summarizes the characteristics of
the 3 subgroups together with the characteristics of the
total patient group.Page 4 of 13
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BMC Cancer 2009, 9:322 http://www.biomedcentral.com/1471-2407/9/322The three subgroups differed significantly with respect to
the number of tumor-positive lymph nodes, tumor size,
and primary treatment (Pearson X2 test, P < 0.001, Table
1). Thus, patients who received CMF more often had only
1-3 involved lymph nodes and also had smaller tumors
(pT1) when compared with untreated patients and with
patients who received anthracycline-based chemotherapy.
Looking at primary treatments, more patients had a
lumpectomy among CMF-treated and patients receiving
no adjuvant chemotherapy than among anthracycline-
treated patients. In addition to this, fewer anthracycline-
treated patients received adjuvant RT. The differences in
number of involved lymph nodes and adjuvant RT were
partly accounted for in the stratification.
TIMP-1 levels and association of TIMP-1 with 
clinicopathological variables
The median TIMP-1 concentration in the tissue extracts
was 12.5 ng/mg of total protein (range, 0-113 ng/mg pro-
tein). Median tumor tissue TIMP-1 levels in subgroups
Kaplan-Meier plot showing the DFS (A) and OS (B) of untreated TIMP-1 low and high patientsFigure 1
Kaplan-Meier plot showing the DFS (A) and OS (B) of untreated TIMP-1 low and high patients. The median 
TIMP-1 concentration of the total patient group (12.5 ng/mg of total protein) was used as cut point (TIMP-1 low patients N = 
57, TIMP-1 high patients N = 45). Cox univariate regression analysis; DFS: HR 0.93, 95% CI 0.58-1.49, P = 0.76; OS: HR 0.72, 
95% CI 0.39-1.33, P = 0.30.
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Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high anthracycline-treated patientsFigure 2
Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high anthracycline-treated patients. The 
median TIMP-1 concentration of the total patient group (12.5 ng/mg of total protein) was used as cut point (TIMP-1 low 
patients N = 46, TIMP-1 high patients N = 53). Cox univariate regression analysis; DFS: HR 1.52, 95% CI 0.88-2.63, P = 0.13; 
OS: HR 2.53, 95% CI 1.19-5.39, P = 0.02.
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BMC Cancer 2009, 9:322 http://www.biomedcentral.com/1471-2407/9/322according to adjuvant treatment were as follows: In CMF-
treated patients 12.0 ng/mg of total protein (range, 0-106
ng/mg); in patients who received an anthracycline-con-
taining regimen 13.5 ng/mg protein (range, 0-51.2 ng/
mg); and in patients who received no adjuvant chemo-
therapy 13.8 ng/mg protein (range, 0-113 ng/mg). These
levels were not significantly different (Kruskal-Wallis
equality-of-populations rank test, P = 0.20, Table 1).
Analyzing the total group of patients, TIMP-1 was signifi-
cantly associated with age as younger patients had signifi-
cantly lower levels of TIMP-1 in their tumors (Spearman
rank correlation analysis, rs = 0.10, P = 0.02). No signifi-
cant association was found between TIMP-1 and number
of tumor-positive lymph nodes, steroid hormone receptor
status, tumor size, grade, adjuvant RT, or type of surgery.
When subgroups according to adjuvant treatment were
analyzed separately we found no significant associations
between TIMP-1 and age, number of tumor-positive
lymph nodes, tumor size, grade, adjuvant RT, or type of
surgery in any of the subgroups. In the subgroup of CMF-
treated patients, however, we found an association
between TIMP-1 and hormone receptor status with higher
tumor tissue TIMP-1 levels in patients with hormone
receptor negative tumors (Mann-Whitney test, P = 0.04).
TIMP-1 and prognosis
The prognostic impact of TIMP-1 was analyzed in the total
patient group and in further detail in the group of patients
who received no adjuvant chemotherapy. In these analy-
ses, TIMP-1 was analyzed both as a continuous log-trans-
formed variable and as a dichotomized variable with
patients divided into two groups of high and low tumor
tissue TIMP-1 levels, respectively, by the median TIMP-1
concentration of the total patient group (12.5 ng/mg pro-
tein). As described in the Statistics part, all analyses were
censored at 60 months and stratified for the number of
involved lymph nodes, RT of the axilla, and hormone
receptor status.
In Cox univariate regression analysis including all 525
patients, increasing tumor tissue TIMP-1 concentrations
were not significantly associated with DFS or OS neither
when analyzed as a continuous log-transformed variable
(DFS: HR 1.15, 95% CI 0.93-1.42, P = 0.20; OS: HR 1.17,
95% CI 0.88-1.57, P = 0.28) nor as a dichotomized varia-
ble (DFS: HR 1.13, 95% CI 0.88-1.43, P = 0.34; OS: HR
1.24, 95% CI 0.89-1.71, P = 0.20).
We then analyzed the subgroup of patients receiving no
adjuvant chemotherapy separately as the outcome of this
group is uninfluenced by systemic treatment. In both uni-
variate and multivariable survival analyses of this sub-
group we found no association between TIMP-1 and
outcome (DFS, OS) neither when including TIMP-1 as a
continuous variable nor as a dichotomized variable
(Table 2). The DFS and OS of TIMP-1 high and low
untreated patients are illustrated in Figure 1A and 1B,
respectively, which show that the curves describing the
two groups are super imposable.
Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high CMF-treated patientsFigure 3
Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high CMF-treated patients. The median 
TIMP-1 concentration of the total patient group (12.5 ng/mg of total protein) was used as cut point (TIMP-1 low patients N = 
172, TIMP-1 high patients N = 152). Cox univariate regression analysis; DFS: HR 1.15, 95% CI 0.82-0.1.61, P = 0.42; OS: HR, 
1.44 (0.91-2.29), P = 0.12.
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BMC Cancer 2009, 9:322 http://www.biomedcentral.com/1471-2407/9/322There were no significant differences among untreated
TIMP-1 high and low patients with respect to clinico-
pathological parameters (type of surgery, age, number of
tumor-positive lymph nodes, tumor size, hormone recep-
tor status, tumor grade, RT; data not shown).
TIMP-1 and prediction
To address the question of a possible predictive impact of
TIMP-1 we analyzed the outcome (DFS, OS) of patients
who had received adjuvant systemic therapy. We used two
different approaches to address this question; both
approaches were considered justified since there appears
to be no, or a modest, association between TIMP-1 and
prognosis in the patients studied here. Consequently, the
reported differences are not due to a combined prognostic
and predictive impact of TIMP-1 but rather a predomi-
nantly predictive one. In our first analysis, we evaluated
the benefit from treatment in TIMP-1 high and low
patients by comparing with the outcome of patients who
did not receive systemic adjuvant therapy, and secondly
we compared the outcome of TIMP-1 high- and low
patients within treatment subgroups.
Comparison with patients who did not receive adjuvant 
chemotherapy
First, we compared DFS of patients treated with adjuvant
anthracycline-containing chemotherapy or adjuvant CMF
with DFS of untreated patients. For this purpose, a varia-
ble combining TIMP-1 status and adjuvant chemotherapy
was created: Patients who received adjuvant chemother-
apy were divided into TIMP-1 high and low groups, again
applying the median TIMP-1 concentration of the total
patient group as a cut point. Patients who did not receive
systemic adjuvant therapy were included as one group
(high and low TIMP-1) for reference purposes.
First, we performed Cox univariate regression analysis
using the untreated patients as a reference. Among anthra-
cycline-treated patients neither TIMP-1 low nor TIMP-1
high patients had a significantly improved survival when
using the untreated patients as a reference group (TIMP-1
low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-
1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).
When comparing the TIMP-1 low and high CMF-treated
groups with the untreated patients group, we found that
both TIMP-1 low and high groups had a significantly bet-
ter DFS than untreated patients (TIMP-1 low patients: HR
0.51, 95% CI 0.36-0.73, P < 0.001; TIMP-1 high patients:
HR 0.58, 95% CI 0.41-0.81, P = 0.002).
We also analyzed the benefit from adjuvant treatment,
when compared with untreated patients, in a multivaria-
ble model. As mentioned our base model included age,
tumor size, malignancy grade, and adjuvant chemother-
Table 2: Univariate and Multivariable survival analyses of the subgroup of untreated patients, N = 102*
Univariate DFS OS
HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 0.96 (0.63-1.45) 0.84 0.72 (0.39-1.33) 0.29
High vs. low 0.93 (0.58-1.49) 0.76 0.72 (0.39-1.33) 0.3
Multivariable DFS OS
HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 0.95 (0.60-1.51) 0.84 0.80 (0.41-1.57) 0.52
High vs. low 0.95 (0.56-1.62) 0.86 0.80 (0.41-1.54) 0.5
Age 41-55 years vs. ≤ 40 years 0.53 (0.31-0.89) 0.02 0.40 (0.21-0.77) 0.01
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 1.76 (0.93-3.33) 0.19 1.77 (0.72-4.36) 0.37
Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 1.35 (0.58-3.14) 2.01 (0.62-6.45)
Grade Unknown vs. poor 0.70 (0.40-1.22) 0.39 0.83 (0.41-1.67) 0.51
Well/moderate vs. poor 0.74 (0.33-1.64) 0.54 (0.18-1.64)
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base 
model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor 
size and grade are similar with TIMP-1 included.Page 7 of 13
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treated with anthracycline-containing chemotherapy a
trend towards a better outcome in TIMP-1 low patients
compared with untreated patients was observed although
neither TIMP-1 low nor TIMP-1 high patients had a signif-
icantly better DFS than untreated patients (TIMP-1 low
patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1
high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90). In
the CMF-treated subgroup both TIMP-1 low and high
patients had a significantly longer DFS than untreated
patients (TIMP-1 low patients: HR 0.48, 95% CI 0.33-
0.69, P < 0.001; TIMP-1 high patients: HR 0.57, 95% CI
0.41-0.81, P = 0.001). In this multivariable model
younger age and increase in tumor size were associated
with a significantly shorter DFS. The results of the multi-
variable analysis combining TIMP-1 status and adjuvant
therapy are shown in Table 3.
In a similar multivariable analysis of OS, a more pro-
nounced difference was found in benefit from anthracy-
cline-based therapy in TIMP-1 low and high patients,
when compared with untreated patients (TIMP-1 low
patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1
high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none
of the groups, though, had a significantly better outcome
than patients who received no adjuvant chemotherapy.
Among CMF-treated patients, both TIMP-1 low and high
patients had a significantly better OS than untreated
patients (TIMP-1 low patients: HR 0.42, 95% CI 0.26-
0.70), P = 0.001; TIMP-1 high patients: HR 0.64, 95% CI
0.41-1.00, P = 0.05). Also in this multivariable model, age
and tumor size were significantly associated with survival.
Comparison of TIMP-1 low- and high patients within treatment 
subgroups
We then compared the outcome after therapy and the
association with increasing tumor tissue TIMP-1 sepa-
rately within each treatment subgroup (anthracycline-
treated, CMF). We performed analyses including TIMP-1
both as a continuous log-transformed variable and as a
dichotomized variable with patients divided into two
groups of high and low tumor tissue TIMP-1 levels,
respectively, by the median TIMP-1 concentration of the
total patient group.
In Cox univariate regression analyses, both in patients
who received adjuvant anthracycline-based chemother-
apy and in CMF-treated patients, we found no statistically
significant associations between TIMP-1 and DFS (Table
4, Figures 2A and 3A); however, in anthracycline-treated
patients, despite the non-significant results, there was a
trend for TIMP-1 high patients to have a worse outcome
than TIMP-1 low patients, especially when analyzing
TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-
2.85, P = 0.07). Additionally, in the anthracycline-treated
group high TIMP-1 was associated with a significantly
shorter OS both when analyzed as a continuous variable
(HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichot-
omized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02)
whereas no differences were observed among TIMP-1 high
Table 3: Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*
HR (95% CI) P
Anthracycline-treatment TIMP-1 low vs. all untreated 0.71 (0.42-1.19) 0.19
TIMP-1 high vs. all untreated 0.97 (0.60-1.57) 0.90
CMF-treatment TIMP-1 low vs. all untreated 0.48 (0.33-0.69) <0.001
TIMP-1 high vs. all untreated 0.57 (0.41-0.81) 0.001
Age 41-55 years vs. ≤ 40 years 0.63 (0.49-0.81) <0.001
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 1.80 (1.33-2.45) <0.001
Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 1.86 (1.26-2.74)
Grade Unknown vs. poor 0.83 (0.61-1.11) 0.08
Well/moderate vs. poor 0.69 (0.49-0.98)
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. All patients N = 525: anthracycline-treated low TIMP-1, 46 
patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated 
(high and low TIMP-1, combined), 102 patients.Page 8 of 13
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Figures 2B and 3B).
We then performed separate multivariable survival analy-
ses in anthracycline-treated and in CMF-treated patients,
respectively (Table 5 and 6). As before, TIMP-1 was added
to the base model first as a continuous and then as a
dichotomized variable. In the analysis of the anthracy-
cline-treated subgroup, TIMP-1 analyzed as a continuous
variable showed a strong tendency for higher levels to be
associated with a shorter DFS (HR 1.75, 95% CI 1.00-
3.07, P = 0.05). In patients who received adjuvant CMF we
found no association between TIMP-1 and DFS; in this
model younger age and increase in tumor size were asso-
ciated with a shorter DFS. When including TIMP-1 in the
multivariable models, the coefficients for the other varia-
bles included were similar. In addition, among patients
treated with adjuvant anthracycline-based therapy we
found a highly significant association with OS both when
included as a continuous (HR 4.19, 95% CI 1.67-10.51, P
= 0.002) and as a dichotomized variable (HR 2.59, 95%
CI 1.14-5.88, P = 0.02). In CMF-treated patients, TIMP-1
was associated with shorter OS only when analyzed as a
dichotomized variable (HR = 1.64, 95% CI 1.02-2.65, P =
0.04).
Among anthracycline-treated patients there were no sig-
nificant differences in clinicopathological characteristics
between TIMP-1 high and low patients; among CMF-
treated patients there were significantly more patients
younger than 40 years in the TIMP-1 low subgroup and
significantly more patients with more than 3 tumor-posi-
tive lymph nodes in the TIMP-1 high subgroup (data not
shown).
Interactions
There were no statistically significant interactions between
TIMP-1 and adjuvant chemotherapy in analyses of DFS.
However, in analyses of OS there was a statistically signif-
icant interaction between TIMP-1 and anthracycline treat-
ment both in a model including only adjuvant therapy
and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and
in the model including age, tumor size and malignancy
grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).
Discussion
We recently reported that metastatic breast cancer patients
with high tumor tissue levels of TIMP-1 had no benefit
from chemotherapy with CMF and anthracycline-contain-
ing regimens suggesting that tissue TIMP-1 may be a pre-
dictive marker for response to chemotherapy [6], and data
from studies of adjuvant treatment are now emerging
[7,8]. TIMP-1 in plasma and serum has been suggested as
a marker of prognosis [12,15-17] and additionally, high
blood levels of TIMP-1 have been shown to predict resist-
ance to endocrine therapy in patients with metastatic
breast cancer [9,10]. It is still unclear, though, exactly how
TIMP-1 is related with prognosis and prediction, and
whether different information may be obtained from
TIMP-1 in different patient subgroups.
In this study, we analyzed the relation between TIMP-1
and prognosis by evaluating outcome (DFS, OS) in the
total group of 525 patients and in a subgroup of patients
who had not received adjuvant chemotherapy and unex-
pectedly found no significant associations. The DFS anal-
ysis of the untreated group is particularly interesting as
this analysis describes only the prognostic impact of
TIMP-1 with no interference from systemic treatment; cur-
rently, this is rarely feasible as most patients, certainly
among lymph node-positive patients, receive systemic
adjuvant treatment. We previously reported a prognostic
Table 4: Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*
DFS OS
HR (95% CI) P HR (95% CI) P
Anthracycline-treated patients TIMP-1
(continuous variable)
1.66 (0.96-2.85) 0.07 3.52 (1.54-8.06) 0.003
TIMP-1
(high vs. low)
1.52 (0.88-2.63) 0.13 2.53 (1.19-5.39) 0.02
CMF-treated patients TIMP-1
(continuous variable)
1.12 (0.84-1.51) 0.44 1.22 (0.82-1.81) 0.32
TIMP-1
(high vs. low)
1.15 (0.82-1.61) 0.42 1.44 (0.91-2.29) 0.12
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.Page 9 of 13
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to confirm this finding in the presently analyzed premen-
opausal untreated patients, who were also included in the
original cohort. However, in the original study many
lymph node-positive patients, in particular premenopau-
sal patients, had received adjuvant systemic treatment and
this may potentially have affected the analysis of prognos-
tic impact. Thus, even if the presently analyzed subgroups
are small, which makes it difficult to detect a modest asso-
ciation with prognosis, the apparent lack of prognostic
impact in the present study suggests that the association of
TIMP-1 with prognosis is limited to, or more pronounced
in, other subgroups of patients.
We then addressed the question of a possible predictive
impact of TIMP-1. Looking at anthracycline-treated
patients, a comparison with patients who did not receive
adjuvant chemotherapy (Table 3) showed that neither
TIMP-1 low nor TIMP-1 high patients treated with anthra-
cycline-based adjuvant therapy had a significantly better
DFS than untreated patients. Thus, treatment with anthra-
cycline-based chemotherapy appears to be associated with
Table 5: Multivariable analyses of anthracycline-treated patients, N = 99*
DFS OS
HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 1.75 (1.00-3.07) 0.05 4.19 (1.67-10.51) 0.002
High vs. low 1.48 (0.84-2.61) 0.17 2.59 (1.14-5.88) 0.02
Age 41-55 years vs. ≤ 40 years 0.68 (0.37-1.25) 0.22 0.80 (0.37-1.72) 0.57
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 2.13 (0.91-4.98) 0.13 3.63 (0.82-16.13) 0.14
Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 2.31 (0.87-6.11) 2.77 (0.54-14.14)
Grade Unknown vs. poor 0.90 (0.43-1.92) 0.88 0.16 (0.02-1.21) 0.06
Well/moderate vs. poor 0.82 (0.35-1.88) 1.11 (0.39-3.15)
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base 
model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor 
size and grade were similar with TIMP-1 included.
Table 6: Multivariable analysis of CMF-treated patients, N = 324*
DFS OS
HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 1.18 (0.87-1.59) 0.28 1.29 (0.87-1.91) 0.20
High vs. low 1.23 (0.87-1.73) 0.25 1.64 (1.02-2.65) 0.04
Age 41-55 years vs. ≤ 40 years 0.60 (0.43-0.85) 0.004 0.53 (0.33-0.84) 0.007
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 1.59 (1.07-2.38) 0.02 2.34 (1.31-4.20) 0.01
Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 1.92 (1.15-3.22) 1.97 (0.92-4.20)
Grade Unknown vs. poor 0.83 (0.55-1.25) 0.24 1.05 (0.60-1.84) 0.62
Well/moderate vs. poor 0.68 (0.43-1.10) 0.74 (0.38-1.46)
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base 
model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor 
size and grade were similar with TIMP-1 included.Page 10 of 13
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but it should be kept in mind that the anthracycline-
treated subgroup is characterized by very poor prognostic
features (larger tumors, many tumor-involved lymph
nodes, Table 1). Moreover, looking closely at the HRs and
CIs of the anthracycline-treated TIMP-1 low and high
groups, TIMP-1 high patients appear to benefit even less
than TIMP-1 low patients from the chemotherapy, com-
pared with patients who received no adjuvant chemother-
apy. This difference between TIMP-1 low and high
patients was even more pronounced in the analysis of OS.
In addition, in the subgroup analyses of anthracycline-
treated patients (Tables 4 and 5) we observed a strong ten-
dency for increasing TIMP-1 levels (continuous variable)
to be associated with shorter DFS, and in the analyses of
OS increasing TIMP-1 was strongly correlated with shorter
survival in both univariate and multivariable analyses. We
speculate that the differences seen in the subgroup analy-
ses are mainly due to a predictive impact of TIMP-1 since
there is a limited prognostic impact of TIMP-1 in this
cohort. The interaction analysis which showed a statisti-
cally significant association between TIMP-1 and anthra-
cycline therapy in the analyses of OS further suggests that
high levels of tumor tissue TIMP-1 are predictive of
reduced benefit from adjuvant anthracycline-based ther-
apy.
Similarly, the benefit from CMF was first analyzed in the
combined model with patients who received no adjuvant
therapy as a reference group (Table 3). This analysis
showed that both TIMP-1 high and TIMP-1 low patients
had a significantly longer survival than untreated patients.
In subgroup analyses of CMF-treated patients the only sig-
nificant association between TIMP-1 and outcome was a
modest association between TIMP-1 and OS in the multi-
variable analysis including TIMP-1 as dichotomized vari-
able (Tables 4 and 6). Thus, in this cohort the benefit from
adjuvant CMF appears to be similar in TIMP-1 high and
low patients.
The endpoint of DFS is uninfluenced by therapy given in
the metastatic setting; yet, the results in the present analy-
ses of OS are stronger in terms of showing statistically sig-
nificant associations, including a significant interaction
between anthracycline treatment and TIMP-1. Since
TIMP-1 is also associated with response to therapy in the
metastatic setting [6] it could be speculated that this influ-
ences the analyses of OS in the present study. Thus, the
statistically significant association in the analyses of OS
illustrates a combination of predictive impact in the adju-
vant as well as in the metastatic setting.
Several of the analyses presented show tendencies rather
than statistically significant results and a number of
aspects related to the patient cohort and the analyses
should be mentioned. Firstly, all survival analyses were
performed first including TIMP-1 as a continuous variable
and then as a dichotomized one employing the median
TIMP-1 concentration as a cut point. However, inclusion
of TIMP-1 as a continuous variable, in particular in analy-
ses of patients treated with anthracycline-based therapy,
showed a stronger association between TIMP-1 and out-
come than those employing the dichotomized variable.
Thus, it could be speculated that the median TIMP-1 con-
centration is not an ideal cut point for separating TIMP-1
low and high patients, however, the limited number of
patients did not allow for analyses employing more than
one cut point.
In addition, the subgroups of patients who received no
adjuvant chemotherapy or anthracycline-based therapy
are small, and the anthracycline-treated group is charac-
terized by having a very poor prognosis based on classical
prognostic parameters. Moreover, the patient cohort
included in the present study consists of premenopausal
lymph node-positive patients who had left-over tumor
extracts stored in the tumor bank. Thus, the cohort does
not represent a consecutively and prospectively collected
cohort but rather a selected one. The diversity of the
patient cohort did complicate the analyses; there were
substantial differences among subgroups with regard to
primary treatment (surgery, RT), tumor size, degree of
lymph node involvement, and patients were following
different treatment protocols employed at different times.
The stratified multivariable models account for the differ-
ences to some extent, but the diversity still should be kept
in mind when interpreting the results. Yet, the use of
archival samples dating as far back as 1979 allowed for
inclusion of an untreated patient group and this offered a
unique opportunity for evaluation of prognosis of high-
risk patients without adjuvant chemotherapy. For ethical
reasons, such studies are not possible today.
All patients included in the study received standard chem-
otherapy based on the physician's judgment and good
clinical practice at the time of treatment and conse-
quently, treatment regimens differ from those currently
employed. The results, though, show an association
between TIMP-1 and lack of benefit from anthracycline-
based therapy, which is widely used in the adjuvant set-
ting. A recent study showed a similar association between
TIMP-1 and decreased benefit from anthracyclines [7],
thus indicating that further validation of TIMP-1 as a pre-
dictive marker for anthracycline sensitivity is justified.
The exact mechanism by which TIMP-1 may affect the sen-
sitivity to certain types of cytotoxic drugs has not been elu-
cidated. However, the ability of TIMP-1 to influence cell
growth and apoptosis is likely to play a role (reviewed in
[4,5]). In keeping with this, in vitro preclinical findingsPage 11 of 13
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induced apoptosis in cells made gene-deficient for the
TIMP-1 gene when compared with the wild-type cells
[26]. We recently extended the in vitro studies to a human
breast carcinoma cell line and showed that cells express-
ing high levels of TIMP-1 protein were significantly less
sensitive to treatment with etoposide and epirubicin than
cells expressing low levels of TIMP-1 [27]. Thus, TIMP-1-
mediated inhibition of chemotherapy-induced apoptosis
could explain the decreased effectiveness of certain cyto-
toxic drugs in tumors producing large amounts of TIMP-1.
Conclusion
This study suggests that patients with TIMP-1 high tumors
benefit less from adjuvant chemotherapy with anthracy-
clines than patients with TIMP-1 low tumors. In the
cohort studied here we were not able to find any, or only
a very limited, prognostic impact of TIMP-1 and still, we
observed a difference in outcome of TIMP-1 high and low
patients after adjuvant anthracycline-based chemother-
apy. We suggest that this difference is due to a predictive
impact of TIMP-1. Despite the small size of the anthracy-
cline-treated subgroup, the analysis of DFS clearly indi-
cated an association between high levels of tumor tissue
TIMP-1 and a shorter survival. Looking at OS, high levels
of TIMP-1 were associated with a significantly shorter sur-
vival and we found a statistically significant interaction
between TIMP-1 and anthracycline therapy. In the sub-
group of CMF-treated patients, we found no consistent
associations between TIMP-1 and survival. The results of
this retrospective analysis are in keeping with other
reports and our findings warrant further validation in pro-
spective studies.
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